Johnson & Johnson (JNJ)

NYQ – Цена в реальном времени. Валюта: USD

224.26

+2.83 (1.28%)

При закрытии: May 12, 2026, 4:00 PM EDT

222.39

-2.01 (-0.89%)

До открытия: May 13, 2026, 5:07 AM EDT

12.05.2026

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

12.05.2026

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

12.05.2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.

11.05.2026

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast.

11.05.2026

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Oral presentations feature CAPLYTA ® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J's leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings TITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami).

10.05.2026

2 Dividend Stocks That Are No-Brainer Buys in May

The geopolitical conflict in the Middle East has pushed oil prices higher and increased concerns about a recession. The S&P 500 index continues to hold near its all-time highs.

08.05.2026

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Johnson & Johnson has increased its dividend for 64 consecutive years. Procter & Gamble recently extended its dividend growth streak to 70 straight years.

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
JNJ	Daiwa Securities	Outperform	undefined >> $203	October 20th 2025
JNJ	Wells Fargo	Overweight	undefined >> $212	October 3rd 2025
JNJ	Guggenheim	Buy	undefined >> $206	September 23rd 2025
JNJ	Erste Group	Buy	undefined >> undefined	July 23rd 2025
JNJ	Leerink Partners	Market Perform	undefined >> $153	May 13th 2025

Johnson & Johnson (JNJ)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

2 Dividend Stocks That Are No-Brainer Buys in May

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

2 Dividend Stocks That Are No-Brainer Buys in May

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Search stocks

Johnson & Johnson (JNJ)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

2 Dividend Stocks That Are No-Brainer Buys in May

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

2 Dividend Stocks That Are No-Brainer Buys in May

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease